1.39

0.72% +0.01

After Hours: 1.42 0.03 +2.16%

BriaCell Therapeutics Corp (BCTX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

BriaCell Therapeutics Corp stock is currently priced at $1.39, with a 24-hour trading volume of 164.55K. It has seen a +0.72% increased in the last 24 hours and a -35.65% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.46 pivot point. If it approaches the $1.22 support level, significant changes may occur.

Previous Close:

$1.38

Open:

$1.47

24h Volume:

164.55K

Market Cap:

$22.21M

Revenue:

Net Income/Loss:

$-13.19M

P/E Ratio:

-10.39

EPS:

-0.1338

Net Cash Flow:

$-27.81M

1W Performance:

-38.22%

1M Performance:

-35.65%

6M Performance:

-68.05%

1Y Performance:

-77.47%

1D Range:

$1.33

$1.49

52W Range:

$1.30

$7.59

BriaCell Therapeutics Corp Stock (BCTX) Company Profile

Name

BriaCell Therapeutics Corp

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

604 921 1810

Address

Bellevue Centre, 235 West 15th Street Suite 300, West Vancouver

Employee

Twitter

Next Earnings Date

2024-06-10

Latest SEC Filings

BCTX's Discussions on Twitter

BriaCell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-14-22	Initiated	H.C. Wainwright	Buy

BriaCell Therapeutics Corp Stock (BCTX) Latest News

A BriaCell Therapeutics Corp. (TSE:BCT) insider increased their holdings by 20% last year - Yahoo Sport Australia

Yahoo Sport Australia

BriaCell Therapeutics (CVE:BCT) Stock Price Down 3.8% - Defense World

Defense World

Closing Bell: Briacell Therapeutics Corp down on Friday (BCT) - The Globe and Mail

The Globe and Mail

Closing Bell: Briacell Therapeutics Corp down on Friday (BCT) - Barchart

Barchart

BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering - GlobeNewswire

GlobeNewswire

BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

GlobeNewswire Inc.

BriaCell Therapeutics Corp Stock (BCTX) Financials Data

BriaCell Therapeutics Corp (BCTX) Net Income 2024

BCTX net income (TTM) was -$13.19 million for the quarter ending October 31, 2023, a -3,102% decrease year-over-year.

BriaCell Therapeutics Corp (BCTX) Cash Flow 2024

BCTX recorded a free cash flow (TTM) of -$27.81 million for the quarter ending October 31, 2023, a -95.17% decrease year-over-year.

BriaCell Therapeutics Corp (BCTX) Earnings per Share 2024

BCTX earnings per share (TTM) was -$1.74 for the quarter ending October 31, 2023, a -4,250% decline year-over-year.

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.